Drug intelligence / Profile preview

RAG-1C

Development stage: Unknown
Lead developer: Ractigen Therapeutics
Administration: Intravitreal, Ophthalmic

Overview

RAG-1C is an investigational drug being developed for the treatment of proliferative vitreoretinopathy, a serious eye disorder characterized by the growth of membranes within the retina that can lead to retinal detachment and vision loss. The drug is currently at the IND (Investigational New Drug) application stage, which means it has not yet entered clinical trials. Specific details about its mechanism of action, modality, or molecular target have not been disclosed in public sources as of now[2][3].

Beyond the preview

Go deeper on RAG-1C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAG-1C.

Explore the full profile